Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

Biotechnology

Healthcare
$2.75 +1.73%

+$0.14 today

Market cap
$56.57M
Beta
2.59
P/E (TTM)
-1.3
EPS (TTM)
-$6.35
52W Low $6.72High $20.56

Volume 0.63M

Average 0.42M

CRBP Account Payables

Amounts the company owes suppliers for goods and services received.

Corbus Pharmaceuticals Holdings, Inc.NASDAQ: CRBP

Account Payables · Q1 FY2026 · quarter ended Mar 2026

Account payables falls 89.3% from a year ago

Account payables stood at $435K at the end of Q1 FY2026, down 89.3% from a year earlier and down 80.4% from the prior quarter. Over 3 fiscal years it compounded at +0.6% a year.

Context

  • Account payables amounted to 0.3% of total assets at the end of Q1 FY2026, down 2.6 pp from a year earlier.
  • Account payables increased in 2 of the last 3 fiscal years.

What to watch

Whether account payables keeps falling in the next quarterly balance sheet after a -89.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$435K-80.4% QoQ
Last fiscal yearDec 2025
$2.22M-53.7% YoY
Year agoMar 2025
$4.07M-89.3% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-89.3%——
1 year-53.7%——
3-year CAGR+0.6%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
2.22M USD
Year-over-year change
-53.7%
4-year CAGR
+5.6%

Account Payables vs competitors

How CRBP compares with its peers on the latest reported figures

  • Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -89.3% is the 9th highest of 10, against a peer median of -19.9%.
  • Account payables amounts to 0.3% of total assets for CRBP, versus a peer median of 2.2%.
CRBP Competitors
Account Payables for CRBP and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IPHAInnate Pharma S.A.Dec 2025€15.04M EUR+89.8%+3.3%24.0%
FBRXForte Biosciences, Inc.Mar 2026$13.08M USD+160.5%+105.4%19.5%
MISTMilestone Pharmaceuticals Inc.Mar 2026$10.02M USD+320.4%+35.6%5.2%
CRDFCardiff Oncology, Inc.Mar 2026$5.48M USD+51.0%+60.5%11.1%
MOLNMolecular Partners AGMar 2026CHF 1.92M CHF-19.9%-2.0%2.2%
ALECAlector, Inc.Mar 2026$1.42M USD-38.8%-26.1%0.6%
RANIRani Therapeutics Holdings, Inc.Mar 2026$858K USD-43.6%-40.4%1.7%
PEPGPepGen Inc.Mar 2026$622K USD-77.0%-15.5%0.4%
CRBPCorbus Pharmaceuticals Holdings, Inc.Mar 2026$435K USD-89.3%+0.6%0.3%
ELTXElicio Therapeutics, Inc.Mar 2026$272K USD-93.3%-37.9%1.2%
Peer median (excluding CRBP) —-19.9%-2.0%2.2%

Competitors are the stored peer set for CRBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents25.01M17M13.72M17.2M28.49M
Short-term Investments72.64M42.19M7.18M131.86M134.78M
Net Receivables00001.5M
Inventory00000
Other Current Assets192.48K192.48K192K3.91M1.52M
Total Current Assets100.2M60.18M23.55M152.98M166.95M
Property, Plant & Equipment (Net)7M5.5M4.04M2.52M1.24M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets523.81K632.77K690K385K0
Total Non-current Assets7.53M6.13M4.73M2.9M1.24M
Total Assets107.73M66.31M28.27M155.88M168.2M
Account Payables1.78M2.17M3.18M4.79M2.22M
Short-term Debt3.86M3.15M16.21M00
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities133.71K36.87K39K2.28M2.86M
Total Current Liabilities17.01M12.64M31.89M11.82M20.69M
Long-term Debt15.64M15.98M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities22.21K22.21K44K00
Total Non-current Liabilities21.61M20.68M3.28M1.63M0
Total Liabilities38.62M33.32M35.18M13.45M20.69M
Common Stock12.52K41701K2K
Retained Earnings(349.73M)(392.08M)(436.68M)(476.89M)(555.43M)
Accumulated OCI(62.45K)(126.09K)(1K)35K(53K)
Other Stockholders Equity00(0)00
Minority Interest00000
Total Equity69.11M32.99M(6.91M)142.43M147.5M
Total Debt26.59M25.09M20.89M3.24M1.63M
Net Debt1.58M8.09M7.16M(13.96M)(26.86M)

Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

Intrinsic Alpha fair value

Locked

Current Price

$2.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.